hydralazine has been researched along with Alloxan Diabetes in 30 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Streptozotocin-induced diabetic mice were administered with either aliskiren (5 or 25 mg/kg/day) using an osmotic pump or hydralazine (2 or 10 mg/kg/day) given in drinking water for two weeks prior to a hind-limb ischemia surgery." | 7.81 | Direct Renin Inhibition with Aliskiren Improves Ischemia-Induced Neovasculogenesis in Diabetic Animals via the SDF-1 Related Mechanism. ( Chang, TT; Chen, JS; Chen, JW; Huang, PH; Lin, CP; Lin, LY; Lin, SJ; Wu, TC, 2015) |
| "Groups of db/db mice, with obesity and type 2 diabetes, were treated with aliskiren (3, 6, 12 and 25 mg kg(-1) day(-1)) or hydralazine (80 mg kg(-1) day(-1)) for 6 weeks, and the protective effects were extensively compared among groups." | 7.76 | Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y, 2010) |
| "We compared the effects of the angiotensin-converting enzyme inhibitor enalapril and a conventional antihypertensive regimen (hydralazine and metoprolol) on kidney function, albuminuria, and glomerular ultrastructure in hypertensive diabetic and nondiabetic rats." | 7.68 | Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. ( Allen, TJ; Clarke, BE; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Papazoglou, D, 1990) |
| "Streptozotocin-induced diabetic mice were administered with either aliskiren (5 or 25 mg/kg/day) using an osmotic pump or hydralazine (2 or 10 mg/kg/day) given in drinking water for two weeks prior to a hind-limb ischemia surgery." | 3.81 | Direct Renin Inhibition with Aliskiren Improves Ischemia-Induced Neovasculogenesis in Diabetic Animals via the SDF-1 Related Mechanism. ( Chang, TT; Chen, JS; Chen, JW; Huang, PH; Lin, CP; Lin, LY; Lin, SJ; Wu, TC, 2015) |
| "Groups of db/db mice, with obesity and type 2 diabetes, were treated with aliskiren (3, 6, 12 and 25 mg kg(-1) day(-1)) or hydralazine (80 mg kg(-1) day(-1)) for 6 weeks, and the protective effects were extensively compared among groups." | 3.76 | Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y, 2010) |
| " We have previously reported that mice overexpressing angiotensinogen in renal proximal tubular cells (RPTC) develop hypertension, albuminuria, and renal injury." | 3.74 | Overexpression of angiotensinogen increases tubular apoptosis in diabetes. ( Brezniceanu, ML; Chan, JS; Chénier, I; Filep, JG; Ingelfinger, JR; Liu, F; Sachetelli, S; Wei, CC; Zhang, SL, 2008) |
| "We have compared the effects of the angiotensin converting enzyme inhibitor, perindopril, and a conventional antihypertensive regimen (triple therapy: hydralazine, reserpine and hydrochlorothiazide) on kidney function and albuminuria in hypertensive diabetic rats." | 3.68 | Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. ( Allen, TJ; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Rumble, JR, 1992) |
| "To evaluate the role of glomerular hypertension, glomerular hypertrophy, glomerular lipid deposition, and plasma cholesterol levels in diabetic glomerulopathy, Munich-Wistar rats received streptozocin and daily insulin injections and were assigned to one of three groups: untreated diabetic (DMC), hydralazine-treated diabetic (DMH), and enalapril-treated diabetic (DME)." | 3.68 | Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. ( Fujihara, CK; Padilha, RM; Zatz, R, 1992) |
| "We compared the effects of the angiotensin-converting enzyme inhibitor enalapril and a conventional antihypertensive regimen (hydralazine and metoprolol) on kidney function, albuminuria, and glomerular ultrastructure in hypertensive diabetic and nondiabetic rats." | 3.68 | Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. ( Allen, TJ; Clarke, BE; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Papazoglou, D, 1990) |
| "The comparative effects of lisinopril, a third generation angiotensin converting enzyme (ACE) inhibitor, on components of the renin-angiotensin system were assessed in normal and in an animal model of diabetes-related hypertension, the streptozotocin-diabetic rat." | 3.67 | Effects of the angiotensin converting enzyme inhibitor, lisinopril, on normal and diabetic rats. ( Hartmann, JF; Hayes, NS; Keegan, ME; Slater, EE; Szemplinski, M, 1988) |
| "Hydralazine is an antihypertensive agent and may act as a xanthine oxidase (XO) inhibitor to reduce uric acid levels in a mouse renal injury model." | 1.72 | Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Lee, HJ; Lin, SC, 2022) |
| "Hydralazine treatment significantly blocked the development of mesangiolysis and microaneurysms, whereas tubulointerstitial injury was not prevented in these mice." | 1.35 | Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. ( Atkinson, MA; Campbell-Thompson, M; Connor, T; Croker, BP; Grant, MB; Hauswirth, WW; Heinig, M; Kosugi, T; Li, Q; Nakagawa, T; Nakayama, T; Segal, MS; Yuzawa, Y; Zhang, L, 2009) |
| "Hydralazine-treated STZ-diabetic rats had serum triglyceride and cholesterol levels that did not differ from controls." | 1.29 | Effect of hydralazine on myocardial plasma membrane fatty acid binding protein (PM-FABP) during diabetes mellitus. ( Heyliger, CE; Powell, DM; Skau, KA, 1995) |
| "Hydralazine treatment did not alter the isoproterenol-induced chronotropic effect in right atrium." | 1.29 | Effects of hydralazine on cardiac responsiveness to adrenergic agonists in streptozotocin-induced diabetic rats. ( Goyal, RK, 1993) |
| "Perindopril was associated with significantly lower AER than lacidipine, whereas lacidipine was more potent in preventing increases in ocular AVC." | 1.29 | Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat. ( Cooper, M; Gin, T; Jerums, G; Joon, TL; Panagiotopoulos, S; Taylor, H, 1996) |
| "Streptozotocin diabetes was induced in an M-SHRSP and SHC hybrid (TC), from which diabetic TC was successively bred to the fifth generation." | 1.27 | Establishment and use of the M strain of stroke-prone spontaneously hypertensive rat. ( Chikugo, T; Higashizawa, T; Morita, N; Ohta, Y; Okamoto, K; Suzuki, T; Yamamoto, K, 1986) |
| "Hydralazine treatment successfully prevented all these alterations." | 1.27 | Effects of hydralazine on streptozotocin-induced diabetic rats: prevention of hyperlipidemia and improvement in cardiac function. ( Goyal, RK; McNeill, JH; Rodrigues, B, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.00) | 18.7374 |
| 1990's | 15 (50.00) | 18.2507 |
| 2000's | 4 (13.33) | 29.6817 |
| 2010's | 3 (10.00) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Leu, JG | 1 |
| Su, WH | 1 |
| Chen, YC | 1 |
| Liang, YJ | 1 |
| Chang, TT | 2 |
| Chiang, CH | 1 |
| Chen, C | 1 |
| Lin, SC | 1 |
| Lee, HJ | 1 |
| Chen, JW | 2 |
| Kesavan, SK | 1 |
| Bhat, S | 1 |
| Golegaonkar, SB | 1 |
| Jagadeeshaprasad, MG | 1 |
| Deshmukh, AB | 1 |
| Patil, HS | 1 |
| Bhosale, SD | 1 |
| Shaikh, ML | 1 |
| Thulasiram, HV | 1 |
| Boppana, R | 1 |
| Kulkarni, MJ | 1 |
| Wu, TC | 1 |
| Huang, PH | 1 |
| Lin, CP | 1 |
| Chen, JS | 1 |
| Lin, LY | 1 |
| Lin, SJ | 1 |
| Kosugi, T | 1 |
| Heinig, M | 1 |
| Nakayama, T | 1 |
| Connor, T | 1 |
| Yuzawa, Y | 1 |
| Li, Q | 1 |
| Hauswirth, WW | 1 |
| Grant, MB | 1 |
| Croker, BP | 1 |
| Campbell-Thompson, M | 1 |
| Zhang, L | 1 |
| Atkinson, MA | 1 |
| Segal, MS | 1 |
| Nakagawa, T | 1 |
| Dong, YF | 1 |
| Liu, L | 1 |
| Kataoka, K | 1 |
| Nakamura, T | 1 |
| Fukuda, M | 1 |
| Tokutomi, Y | 1 |
| Nako, H | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Nordquist, JE | 1 |
| Göktürk, C | 1 |
| Oreland, L | 1 |
| Liu, F | 1 |
| Brezniceanu, ML | 1 |
| Wei, CC | 1 |
| Chénier, I | 1 |
| Sachetelli, S | 1 |
| Zhang, SL | 1 |
| Filep, JG | 1 |
| Ingelfinger, JR | 1 |
| Chan, JS | 1 |
| Heyliger, CE | 1 |
| Powell, DM | 1 |
| Skau, KA | 1 |
| Goyal, RK | 2 |
| Rodrigues, B | 2 |
| Grassby, PF | 1 |
| Battell, ML | 1 |
| Lee, SY | 1 |
| McNeill, JH | 3 |
| Huijberts, M | 1 |
| Wolffenbuttel, B | 1 |
| Crijns, F | 1 |
| Kruseman, AN | 1 |
| Bemelmans, M | 1 |
| Van Essen, H | 1 |
| Smits, J | 1 |
| Boudier, HS | 1 |
| O'Brien, RC | 3 |
| Cooper, ME | 3 |
| Jerums, G | 4 |
| Doyle, AE | 3 |
| Gin, T | 1 |
| Joon, TL | 1 |
| Panagiotopoulos, S | 1 |
| Cooper, M | 1 |
| Taylor, H | 1 |
| Fukui, T | 1 |
| Ishizaka, N | 1 |
| Rajagopalan, S | 1 |
| Laursen, JB | 1 |
| Capers, Q | 1 |
| Taylor, WR | 1 |
| Harrison, DG | 1 |
| de Leon, H | 1 |
| Wilcox, JN | 1 |
| Griendling, KK | 1 |
| Tang, Z | 1 |
| Shou, I | 1 |
| Wang, LN | 1 |
| Fukui, M | 1 |
| Tomino, Y | 1 |
| Koenen, C | 1 |
| Lang, C | 1 |
| Kempe, HP | 1 |
| Werle, E | 1 |
| Hasslacher, C | 1 |
| Yu, Z | 1 |
| Teschner, M | 1 |
| Schaefer, RM | 1 |
| Bahner, U | 1 |
| Heidland, A | 1 |
| Rumble, JR | 1 |
| Allen, TJ | 2 |
| Fujihara, CK | 1 |
| Padilha, RM | 1 |
| Zatz, R | 1 |
| Burns, AH | 1 |
| Burns, LA | 1 |
| Jurenka, LU | 1 |
| Summer, WR | 1 |
| Papazoglou, D | 1 |
| Clarke, BE | 1 |
| Sunaga, K | 1 |
| Ogihara, M | 1 |
| Sato, T | 1 |
| Nara, Y | 1 |
| Note, S | 1 |
| Yamori, Y | 1 |
| Baba, T | 1 |
| Sawicki, PT | 1 |
| Hartmann, JF | 1 |
| Szemplinski, M | 1 |
| Hayes, NS | 1 |
| Keegan, ME | 1 |
| Slater, EE | 1 |
| Okamoto, K | 1 |
| Yamamoto, K | 1 |
| Morita, N | 1 |
| Ohta, Y | 1 |
| Chikugo, T | 1 |
| Higashizawa, T | 1 |
| Suzuki, T | 1 |
| Shirasaki, Y | 1 |
| Masumura, H | 1 |
| Akashi, A | 1 |
1 review available for hydralazine and Alloxan Diabetes
| Article | Year |
|---|---|
[Nephropathy in type 1 diabetes mellitus. Current experimental and clinical aspects].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Dia | 1992 |
29 other studies available for hydralazine and Alloxan Diabetes
| Article | Year |
|---|---|
Hydralazine attenuates renal inflammation in diabetic rats with ischemia/reperfusion acute kidney injury.
Topics: Acute Kidney Injury; Animals; Cells, Cultured; Coculture Techniques; Diabetes Mellitus, Experimental | 2021 |
Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy.
Topics: Allopurinol; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose | 2022 |
Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation.
Topics: Animals; Blood Urea Nitrogen; Cholesterol; Creatinine; Diabetes Mellitus, Experimental; Glycation En | 2013 |
Direct Renin Inhibition with Aliskiren Improves Ischemia-Induced Neovasculogenesis in Diabetic Animals via the SDF-1 Related Mechanism.
Topics: Amides; Animals; Antibodies, Monoclonal; Blood Pressure; Chemokine CXCL12; Diabetes Mellitus, Experi | 2015 |
Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Diabetes Mellitus, Experimental | 2009 |
Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes.
Topics: Amides; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Experiment | 2010 |
Semicarbazide-sensitive amine oxidase (SSAO) gene expression in alloxan-induced diabetes in mice.
Topics: Adipose Tissue; Alloxan; Amine Oxidase (Copper-Containing); Animals; Blood Glucose; Carbidopa; Diabe | 2002 |
Overexpression of angiotensinogen increases tubular apoptosis in diabetes.
Topics: Albuminuria; Angiotensinogen; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protei | 2008 |
Effect of hydralazine on myocardial plasma membrane fatty acid binding protein (PM-FABP) during diabetes mellitus.
Topics: Animals; Antihypertensive Agents; Carrier Proteins; Diabetes Mellitus, Experimental; Fatty Acid-Bind | 1995 |
Effects of hydralazine on cardiac responsiveness to adrenergic agonists in streptozotocin-induced diabetic rats.
Topics: Adrenergic Agonists; Analysis of Variance; Animals; Atrial Function; Diabetes Mellitus, Experimental | 1993 |
Hypertriglyceridemia in experimental diabetes: relationship to cardiac dysfunction.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Cholesterol; Clofibrate; Diabetes Mellitus, Experim | 1994 |
Inhibition of angiotensin-converting enzyme reduces urinary albumin excretion but not regional albumin clearance in experimental diabetes.
Topics: Albumins; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B | 1993 |
The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressu | 1993 |
Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Press | 1996 |
p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Biphenyl Compounds; Blood Pressure; Diabete | 1997 |
Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Glucose; Captopril; Catalase; Diabetes Mellitu | 1997 |
The influence of the ACE inhibitor lisinopril on the glomerular metabolism of proteolytic enzymes in diabetic rats.
Topics: Acetylglucosaminidase; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressur | 2000 |
Blood pressure and heart rate response to vasoactive agents in conscious diabetic rats.
Topics: Acetylcholine; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Heart Rate; Hydralazine; Is | 1992 |
Antihypertensive therapy in a model combining spontaneous hypertension with diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Gluco | 1992 |
Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy.
Topics: Albuminuria; Analysis of Variance; Animals; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; | 1992 |
Myocardial metabolic effects of in vivo hydralazine treatment of streptozotocin-diabetic rats.
Topics: Animals; Cholesterol; Diabetes Mellitus, Experimental; Dichloroacetic Acid; Female; Glucose; Heart; | 1991 |
Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
Topics: Administration, Oral; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Melli | 1990 |
Effects of calcium channel blockers and hydralazine on plasma glucose levels in streptozotocin-induced diabetic rats in vivo.
Topics: Animals; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Catecholamines; Diabetes Mellitus, | 1990 |
Effect of calcium antagonists on hypertension and diabetes in new hypertensive diabetic models.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diltiazem; Disea | 1987 |
Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat: are these effects specific for enalapril?
Topics: Albuminuria; Animals; Basement Membrane; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic N | 1989 |
Effects of the angiotensin converting enzyme inhibitor, lisinopril, on normal and diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Diabetes Mellitus, Experimental; | 1988 |
Establishment and use of the M strain of stroke-prone spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Hydralazin | 1986 |
[Effect of an antihypertensive drug, budralazine, on glucose and lipid metabolism in diabetic SHR].
Topics: Animals; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 1986 |
Effects of hydralazine on streptozotocin-induced diabetic rats: prevention of hyperlipidemia and improvement in cardiac function.
Topics: Animals; Antihypertensive Agents; Diabetes Mellitus, Experimental; Heart Atria; Heart Rate; Hydralaz | 1986 |